166 related articles for article (PubMed ID: 37817699)
1. Application Of Multigene Panel Detection In Breast Cancer.
Zhao Y; Xiong D; Yang B; Xia S; Zhang X
J Pak Med Assoc; 2023 Sep; 73(9):1862-1868. PubMed ID: 37817699
[TBL] [Abstract][Full Text] [Related]
2. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis.
Harnan S; Tappenden P; Cooper K; Stevens J; Bessey A; Rafia R; Ward S; Wong R; Stein RC; Brown J
Health Technol Assess; 2019 Jun; 23(30):1-328. PubMed ID: 31264581
[TBL] [Abstract][Full Text] [Related]
3. Clinical Utility of Multigene Profiling Assays in Early-Stage Invasive Breast Cancer: An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline.
Blanchette P; Sivajohanathan D; Bartlett J; Eisen A; Feilotter H; Pezo R; Turashvili G; Williams P
Curr Oncol; 2022 Apr; 29(4):2599-2615. PubMed ID: 35448187
[TBL] [Abstract][Full Text] [Related]
4. Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management: a systematic review and cost-effectiveness analysis.
Ward S; Scope A; Rafia R; Pandor A; Harnan S; Evans P; Wyld L
Health Technol Assess; 2013 Oct; 17(44):1-302. PubMed ID: 24088296
[TBL] [Abstract][Full Text] [Related]
5. The multigene classifiers 95GC/42GC/155GC for precision medicine in ER-positive HER2-negative early breast cancer.
Naoi Y; Tsunashima R; Shimazu K; Noguchi S
Cancer Sci; 2021 Apr; 112(4):1369-1375. PubMed ID: 33544932
[TBL] [Abstract][Full Text] [Related]
6. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401
[TBL] [Abstract][Full Text] [Related]
7. Recommendations from the EGAPP Working Group: does the use of Oncotype DX tumor gene expression profiling to guide treatment decisions improve outcomes in patients with breast cancer?
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group*
Genet Med; 2016 Aug; 18(8):770-9. PubMed ID: 26681310
[TBL] [Abstract][Full Text] [Related]
8. [A Review Multigene Assays for Clinical Utility in Breast Cancer].
Araki K; Ito Y
Gan To Kagaku Ryoho; 2016 Nov; 43(11):1332-1340. PubMed ID: 27899774
[TBL] [Abstract][Full Text] [Related]
9. Multigene Signature Panels and Breast Cancer Therapy: Patterns of Use and Impact on Clinical Decision Making.
Bhutiani N; Egger ME; Ajkay N; Scoggins CR; Martin RC; McMasters KM
J Am Coll Surg; 2018 Apr; 226(4):406-412.e1. PubMed ID: 29366844
[TBL] [Abstract][Full Text] [Related]
10. A narrative review of five multigenetic assays in breast cancer.
Zeng C; Zhang J
Transl Cancer Res; 2022 Apr; 11(4):897-907. PubMed ID: 35571670
[TBL] [Abstract][Full Text] [Related]
11. [Chinese expert consensus on multigene testing for adjuvant treatment of HR-positive, HER-2 negative early breast cancer(2023 edition)].
;
Zhonghua Zhong Liu Za Zhi; 2023 Oct; 45(10):863-870. PubMed ID: 37875422
[TBL] [Abstract][Full Text] [Related]
12. Avoiding over- and undertreatment in patients with resected node-positive breast cancer with the use of gene expression signatures: are we there yet?
Matikas A; Foukakis T; Swain S; Bergh J
Ann Oncol; 2019 Jul; 30(7):1044-1050. PubMed ID: 31131397
[TBL] [Abstract][Full Text] [Related]
13. The Clinical Research and Latest Application of Genomic Assays in Early-Stage Breast Cancer.
Chen K; Wu J; Fang Z; Shao X; Wang X
Technol Cancer Res Treat; 2022; 21():15330338221117402. PubMed ID: 36976899
[TBL] [Abstract][Full Text] [Related]
14. The impact of Oncotype DX testing on adjuvant chemotherapy decision making in 1-3 node positive breast cancer.
Malam Y; Rabie M; Geropantas K; Alexander S; Pain S; Youssef M
Cancer Rep (Hoboken); 2022 Aug; 5(8):e1546. PubMed ID: 34664429
[TBL] [Abstract][Full Text] [Related]
15. Budget impact of the Oncotype DX® test compared to other gene expression tests in patients with early breast cancer in Germany.
Lux MP; Minartz C; Müller-Huesmann H; Sandor MF; Herrmann KH; Radeck-Knorre S; Neubauer AS
Cancer Treat Res Commun; 2022; 31():100519. PubMed ID: 35093682
[TBL] [Abstract][Full Text] [Related]
16. [Chinese expert consensus on multigene testing for postoperatively adjuvant treatment of hormone receptor-positive, HER2-negative early breast cancer].
;
Zhonghua Zhong Liu Za Zhi; 2022 Jan; 44(1):54-59. PubMed ID: 35073648
[TBL] [Abstract][Full Text] [Related]
17. Recommendations from the European Commission Initiative on Breast Cancer for multigene testing to guide the use of adjuvant chemotherapy in patients with early breast cancer, hormone receptor positive, HER-2 negative.
Giorgi Rossi P; Lebeau A; Canelo-Aybar C; Saz-Parkinson Z; Quinn C; Langendam M; Mcgarrigle H; Warman S; Rigau D; Alonso-Coello P; Broeders M; Graewingholt A; Posso M; Duffy S; Schünemann HJ;
Br J Cancer; 2021 Apr; 124(9):1503-1512. PubMed ID: 33597715
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of the Oncotype DX Breast Recurrence Score test in node-positive early breast cancer.
Berdunov V; Millen S; Paramore A; Hall P; Perren T; Brown R; Griffin J; Reynia S; Fryer N; Longworth L
J Med Econ; 2022; 25(1):591-604. PubMed ID: 35416089
[TBL] [Abstract][Full Text] [Related]
19. Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: Update of the ASCO Endorsement of the Cancer Care Ontario Guideline.
Henry NL; Somerfield MR; Abramson VG; Ismaila N; Allison KH; Anders CK; Chingos DT; Eisen A; Ferrari BL; Openshaw TH; Spears PA; Vikas P; Stearns V
J Clin Oncol; 2019 Aug; 37(22):1965-1977. PubMed ID: 31206315
[TBL] [Abstract][Full Text] [Related]
20. Initial experience with the Oncotype DX assay in decision-making for adjuvant therapy of early oestrogen receptor-positive breast cancer in Hong Kong.
Cheung PS; Tong AC; Leung RC; Kwan WH; Yau TC
Hong Kong Med J; 2014 Oct; 20(5):401-6. PubMed ID: 24948666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
